Pemetrexed Pfizer (previously known as Pemetrexed Hospira UK Limited)
Country: Unjoni Ewropea
Lingwa: Ingliż
Sors: EMA (European Medicines Agency)
Fuljett ta 'informazzjoni
(PIL)
28-07-2021
Karatteristiċi tal-prodott
(SPC)
28-07-2021
Rapport ta 'Valutazzjoni Pubblika
(PAR)
28-07-2021
Ingredjent attiv:
pemetrexed ditromethamine
Disponibbli minn:
Pfizer Europe MA EEIG
Kodiċi ATC:
L01BA04
INN (Isem Internazzjonali):
pemetrexed
Grupp terapewtiku:
Folic acid analogues, ANTIMETABOLITES
Żona terapewtika:
Carcinoma, Non-Small-Cell Lung; Mesothelioma
Indikazzjonijiet terapewtiċi:
Malignant pleural mesotheliomaPemetrexed Hospira UK Limited in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.Non-small cell lung cancerPemetrexed Hospira UK Limited in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see SmPC section 5.1).Pemetrexed Hospira UK Limited is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see SmPC section 5.1).Pemetrexed Hospira UK Limited is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see SmPC section 5.1).
Sommarju tal-prodott:
Revision: 7
L-istatus ta 'awtorizzazzjoni:
Withdrawn
Data ta 'l-awtorizzazzjoni:
2017-04-24
Fuljett ta 'informazzjoni
39
B. PACKAGE LEAFLET
Medicinal product no longer authorised
40
PACKAGE LEAFLET: INFORMATION FOR THE USER
PEMETREXED PFIZER 100 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR
INFUSION
PEMETREXED PFIZER 500 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR
INFUSION
PEMETREXED PFIZER 1,000 MG POWDER FOR CONCENTRATE FOR SOLUTION FOR
INFUSION
pemetrexed
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START RECEIVING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Pemetrexed Pfizer is and what it is used for
2.
What you need to know before you use Pemetrexed Pfizer
3.
How to use Pemetrexed Pfizer
4.
Possible side effects
5.
How to store Pemetrexed Pfizer
6.
Contents of the pack and other information
1.
WHAT PEMETREXED PFIZER IS AND WHAT IT IS USED FOR
Pemetrexed Pfizer is a medicine used in the treatment of cancer.
Pemetrexed Pfizer is given in combination with cisplatin, another
anti-cancer medicine, as treatment
for malignant pleural mesothelioma, a form of cancer that affects the
lining of the lung, to patients who
have not received prior chemotherapy.
Pemetrexed Pfizer is also given in combination with cisplatin for the
initial treatment of patients with
advanced stage of lung cancer.
Pemetrexed Pfizer can be prescribed to you if you have lung cancer at
an advanced stage if your
disease has responded to treatment or it remains largely unchanged
after initial chemotherapy.
Pemetrexed Pfizer is also a treatment for patients with advanced stage
of lung cancer whose disease
has progressed after other initial chemotherapy has been used.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE PEMETREXED PFIZER
_ _
DO NOT USE PEMETREXED PFIZER
-
if you are allergic to pemetrexed or any of the other ingredients of
this medic
Aqra d-dokument sħiħ
Karatteristiċi tal-prodott
1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
Medicinal product no longer authorised
2
1.
NAME OF THE MEDICINAL PRODUCT
Pemetrexed Pfizer 100 mg powder for concentrate for solution for
infusion
Pemetrexed Pfizer 500 mg powder for concentrate for solution for
infusion
Pemetrexed Pfizer 1,000 mg powder for concentrate for solution for
infusion
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Pemetrexed Pfizer 100 mg powder for concentrate for solution for
infusion
Each vial contains 100 mg of pemetrexed (as pemetrexed
ditromethamine).
Pemetrexed Pfizer 500 mg powder for concentrate for solution for
infusion
Each vial contains 500 mg of pemetrexed (as pemetrexed
ditromethamine).
Pemetrexed Pfizer 1,000 mg powder for concentrate for solution for
infusion
Each vial contains 1,000 mg of pemetrexed (as pemetrexed
ditromethamine).
After reconstitution (see section 6.6), each vial contains 25 mg/ml of
pemetrexed.
For the full list of excipients, see section 6.1.
3.
PHARMACEUTICAL FORM
Powder for concentrate for solution for infusion.
A white to light yellow or green-yellow lyophilised powder.
4.
CLINICAL PARTICULARS
4.1
THERAPEUTIC INDICATIONS
Malignant pleural mesothelioma
Pemetrexed Pfizer in combination with cisplatin is indicated for the
treatment of chemotherapy naïve
patients with unresectable malignant pleural mesothelioma.
Non-small cell lung cancer
Pemetrexed Pfizer in combination with cisplatin is indicated for the
first-line treatment of patients with
locally advanced or metastatic non-small cell lung cancer other than
predominantly squamous cell
histology (see section 5.1).
Pemetrexed Pfizer is indicated as monotherapy for the maintenance
treatment of locally advanced or
metastatic non-small cell lung cancer other than predominantly
squamous cell histology in patients
whose disease has not progressed immediately following platinum-based
chemotherapy (see section
5.1).
Medicinal product no longer authorised
3
Pemetrexed Pfizer is indicated as monotherapy for the second-line
treatment of patients with locally
advance
Aqra d-dokument sħiħ
